Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Healthy Volunteer
Researchers are evaluating whether skipping postoperative radiotherapy PORT to regional lymph nodes in patients with oral cavity squamous cell carcinoma OCSCC who have pN0 or pN1 neck status can achieve similar treatment outcomes. This phase IIIII randomized trial focuses on patients who have undergone radical surgery with adequate lymph node dissection and have high-risk features such as positive or close margins, lymphovascular or perineural invasion, or advanced primary tumor stage. The study addresses the uncertain benefits and potential side effects of radiotherapy to regional lymphatics in this group. Participants are randomly assigned to one of two groups one receiving standard PORT to both the primary tumor bed and regional lymphatics, and the other receiving PORT only to the primary tumor bed while omitting radiotherapy to regional lymph nodes. Radiotherapy is delivered as intensity-modulated radiation therapy IMRT at doses of 66Gy33 fractions, 60Gy30 fractions, or 50Gy20 fractions. In cases of positive surgical margins, weekly cisplatin chemotherapy is given during radiotherapy. The trial excludes patients with more extensive nodal disease pN2 or pN3 and those requiring re-irradiation. Participants will be monitored over two years to assess regional control of cancer, local control, disease-free survival, overall survival, and treatment-related toxicities including acute and late side effects. Swallowing function and quality of life are also evaluated through questionnaires. The study requires timely initiation of radiotherapy, completion of specific quality of life tools, and long-term follow-up visits. Safety and effectiveness outcomes will help determine if omitting radiotherapy to regional lymphatics is feasible without compromising cancer control.
Actively Recruiting
Researchers are investigating the use of lisaftoclax combined with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma CLLSLL who have previously been treated with BTK inhibitors. This global, open-label, phase III study aims to evaluate the effectiveness and safety of this combination compared to BTK inhibitor alone in patients who have been on BTK inhibitor monotherapy for at least 12 months. About 440 participants will be randomly assigned to one of two groups one will receive lisaftoclax together with a BTK inhibitor, and the other will receive only a BTK inhibitor. The study uses a parallel design where participants are allocated equally to each treatment arm to compare outcomes clearly. Both treatments are administered under medical supervision, and the study is open-label, meaning both the researchers and participants know which treatment is given. Participants will be assessed regularly over the course of the study, with evaluations including disease progression measured at 12 months and overall survival also tracked at 12 months. Eligibility screening includes assessments of performance status, bone marrow, kidney, and liver function, as well as consent to follow the study schedule. The research team monitors safety and treatment effects throughout the trial, which is expected to complete by late 2027.
Actively Recruiting
Researchers are conducting a Phase 1, open-label, dose escalation study to assess the safety, pharmacokinetics PK, and pharmacodynamics PD of an oral drug called AUR112 in patients with relapsed advanced lymphomas. This first-in-human trial aims to find safe and tolerable doses of AUR112 for future studies. The study is led by Aurigene Discovery Technologies Limited and focuses on patients with relapsed or refractory non-Hodgkin lymphoma NHL, chronic lymphocytic leukemia CLL, or Hodgkin disease who have exhausted other effective therapies. Participants will receive AUR112 once daily at increasing dose levels ranging from 100 mg to 1200 mg. The dose escalation follows a classic 33 design, where safety and biological activity data guide dose increases. The study will continue increasing doses until safety limits are reached or biologically active doses are identified. This approach helps determine the most appropriate doses for future clinical trials. During the study, participants will be closely monitored for dose-limiting toxicities and treatment-related adverse events over the first 28 days cycle 1. Researchers will also measure various PK parameters like maximum concentration, time to maximum concentration, and area under the curve on specific days. Assessments include laboratory tests, physical exams, and safety evaluations. The study will help identify doses for further research while ensuring participant safety throughout the trial period.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new way to deliver radiation therapy for patients with head and neck squamous cell carcinomas HNSCC in the oropharynx, larynx, and hypopharynx. This trial compares standard intensity-modulated radiotherapy IMRT with a specialized approach called SWOAR IMRT that aims to protect swallowing and aspiration-related structures and the contralateral submandibular gland. The goal is to reduce swallowing difficulties and aspiration risks after treatment. Participants will be randomly assigned to receive either the standard IMRT combined with chemotherapy or the SWOAR IMRT with chemotherapy. Cisplatin chemotherapy is given weekly during radiation at a specified dose when indicated. Both treatments involve radical concurrent chemoradiotherapy or radiotherapy planned for the tumor and lymph nodes. The trial follows patients over time to compare effects on swallowing and other outcomes. Participants will complete questionnaires assessing swallowing function and quality of life before treatment, at the end of treatment, and at multiple follow-up points up to two years. Swallowing safety will also be measured using specialized endoscopic exams. Researchers will monitor treatment side effects weekly during radiation and at follow-up visits. Tumor control and overall survival will be assessed up to five years after treatment, with long-term toxicity and quality of life evaluations included.
Actively Recruiting
Researchers are evaluating a shorter, hypo-fractionated radiotherapy schedule compared to the conventional longer course for patients with squamous cell carcinoma of the head and neck following surgery. This study aims to test if reducing the number of radiation fractions by half can control cancer growth as well as the standard treatment. The trial addresses the need for more convenient, resource-saving treatment options, especially valuable in settings with limited radiotherapy availability. The study compares two radiation therapy schedules given after surgery the standard regimen delivering 60 Gy over 30 fractions in 6 weeks, and a hypo-fractionated regimen delivering 4 Gy over 15 fractions in 3 weeks. Both treatments are given five days per week. Advances in radiation delivery techniques allow better targeting of tumors while protecting nearby organs, making hypo-fractionation a feasible option. This approach also aligns with practices in other cancers where shorter radiation courses have shown similar outcomes. Participants will receive their assigned radiotherapy schedule and be followed for up to two years. Researchers will monitor cancer control in the treated area, swallowing function, disease-free survival, overall survival, quality of life, and both short-term and long-term side effects using various toxicity scales. The study includes detailed assessments and long-term follow-up to evaluate the safety and effectiveness of the hypo-fractionated radiation compared to the conventional schedule.